Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Pharmaceutical Executive June 1, 2007 Jill Wechsler	Washington Report: Shop and Compare Insurers and payers believe that more comparative information on medical treatments will save money and improve care, but such analysis may be costly to pharma.
Pharmaceutical Executive July 3, 2007 Humphrey Taylor	Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change.
Pharmaceutical Executive September 1, 2013 Jordan Sarver	Pathology in the Era of Personalized Medicine With their knowledge of molecular genetics, Pathologists are transforming the way healthcare is provided.
Pharmaceutical Executive July 1, 2005	Marketing to Professionals: Shaping the Future of Medicine Pharma will focus on approving safer, more effective drugs that have real-life applications.
Pharmaceutical Executive July 1, 2006 Jill Wechsler	Washington Report: Hard Evidence The push for more useful information on medication effectiveness is shaping drug development and reimbursement.
Pharmaceutical Executive September 1, 2011 Richard Gliklich	The Power of Observation Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
Nursing Management September 2010 Richard Hader	The evidence that isn't... Interpreting research When patients seek a healthcare practitioner for services, they believe that the delivered care is based on proven science. But reality is far from patient perception. In fact, most care is still based on anecdote, not evidence.
Chemistry World July 2010	Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
Pharmaceutical Executive May 1, 2006	Marketing to Professionals: Ensuring Equality An interview with the National Medical Association president and medical director of the Northwest Indiana Dialysis Center on the racial issues surrounding enrollment of seniors in Medicare Part D, targeted advertising and promotion, and participation of minorities in clinical trials.
Pharmaceutical Executive March 1, 2011 Jerry Coamey	Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution
Information Today April 28, 2011	NIH Launches New Resource on Complementary and Alternative Medicine This new resource seeks to provide health care providers with the tools necessary to learn about the various CAM practices and products.
Chemistry World August 7, 2013 Emma Stoye	AllTrials releases plan for clinical trial reporting The organizations behind AllTrials, a public campaign calling for detailed information on clinical trials to be publically available, have put together a detailed plan on how to achieve clinical trial reporting on a global scale.
Pharmaceutical Executive April 1, 2011	Bridging the HCP-Patient Gap Here's what's necessary to bridge the gap between the patient revolution and healthcare provider in the 21st century.
Information Today October 10, 2013	ACP Smart Medicine Joins OvidSP Wolters Kluwer Health expanded its partnership with the American College of Physicians, making ACP Smart Medicine available on Wolters Kluwer Health's OvidSP medical research platform.
Pharmaceutical Executive November 1, 2011 Elizabeth O. Coulton	Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
Pharmaceutical Executive March 1, 2013 Ken Getz	Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol.
Pharmaceutical Executive September 1, 2005 Wolfgang Klietmann	Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact.
Managed Care July 2005 Martin Sipkoff	Support Grows for Establishing National Clinical Trial Registry Stakeholders are pushing for a national clinical trial registry, and efforts by UnitedHealth Group are in the forefront. Medical journals are setting hard and fast rules.
Chemistry World June 26, 2012 Sarah Houlton	Roche rapped for side-effect reporting failure Roche has been rapped by the European Medicines Agency for failing to report a large number of potential drug side-effects. The UK's Medicines and Healthcare products Regulatory Agency identified deficiencies in the company's medicine safety reporting system.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Bio-IT World August 13, 2003 John Rhodes	Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert.
Chemistry World October 17, 2012 Maria Burke	GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency.
Pharmaceutical Executive May 1, 2007 Steve Singer	Medical Education: Community of Change Continuing medical education professionals need not reinvent the wheel to accomplish more. But we do have to better align our approaches to the way in which healthcare is actually delivered.
Bio-IT World March 2007 Michael A. Greeley	Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities.
Pharmaceutical Executive October 1, 2011	Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public.
Managed Care December 2005 Ricardo Guggenheim	Putting EBM To Work (Easier Said Than Done) Through widespread implementation of evidence-based medicine, the United States has its best chance of erasing the variations in care that currently extract such huge costs -- both human and financial -- from the health care system.
Pharmaceutical Executive February 1, 2012 Sarah Krug	Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
Knowledge@Wharton August 27, 2003	Code Blue: Combating Rising Healthcare Costs Calls for Strong Medicine It's been said many times over that the U.S. healthcare industry is a sick patient in search of a cure. The metaphor is a grim reflection of how the country is coping with an aging population, rising costs and an inefficient healthcare delivery system.
Bio-IT World May 9, 2003 Mark D. Uehling	Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper.
Pharmaceutical Executive November 1, 2013	Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation.
AskMen.com Richard Stevens	Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process.
Managed Care July 2007 Smith et al.	Determining the Cost-Effectiveness of a Computer-Based Smoking Cessation Intervention in Primary Care From a physician's practice perspective, the stage-based computer tailored intervention was cost-effective relative to standard care. Incorporation of partial behavior change into the model further enhanced the cost-effectiveness ratio.
Pharmaceutical Executive October 1, 2005 Lisa Grimes	Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
Bio-IT World August 13, 2002 Mark D. Uehling	Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way?
Pharmaceutical Executive June 1, 2014 O'Connor et al.	Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs.
Nursing Management November 2009 Kathleen Russell-Babin	Seeing through the clouds in evidence-based practice Evidence-based practice is analyzing the research available as critically as possible, placing the findings in the context of your organization, and adding the perspectives and judgment of clinicians and patients.
Pharmaceutical Executive May 1, 2006 Madison, Chan & Seeger	Making the Link The FDA recognizes that a new drug standard must evolve -- one of routine, proactive safety surveillance. But post-marketing safety studies are too slow. Here's how pharmaceuticals are using claims databases to solve the problem.
Information Today May 19, 2015	Wolters Kluwer Health and NextGen Healthcare Integrate Solutions NextGen Healthcare will integrate Wolters Kluwer Health's ProVation Clinic Note into its NextGen Now platform.
Pharmaceutical Executive May 1, 2007	Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge.
Pharmaceutical Executive September 1, 2012 Robin Hertz	The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.